Feedback
Settings

Settings

Goto Application

1. EP3917958 - TREATMENT OF NEUROTOXICITY AND / OR CYTOKINE RELEASE SYNDROME

PermaLink
Office
European Patent Office
Application Number 20702691
Application Date 29.01.2020
Publication Number 3917958
Publication Date 08.12.2021
Publication Kind A1
IPC
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
CPC
C07K 2319/03
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
01containing a localisation/targetting motif
03containing a transmembrane segment
C07K 2319/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
33fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
A61K 38/2006
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
2006IL-1
Applicants AUTOLUS LTD
Inventors PEDDAREDDIGARI VIJAY
Designated States
Priority Data 201901187 29.01.2019 GB
Title
(DE) BEHANDLUNG VON NEUROTOXIZITÄT UND/ODER ZYTOKINFREISETZUNGSSYNDROM
(EN) TREATMENT OF NEUROTOXICITY AND / OR CYTOKINE RELEASE SYNDROME
(FR) TRAITEMENT DE LA NEUROTOXICITÉ ET/OU DU SYNDROME DE LIBÉRATION DE CYTOKINES
Abstract
(EN) The present invention relates to the use of an IL-1β inhibitor for the prevention and/or treatment of neurotoxicity and/or cytokine release syndrome in a subject undergoing immunotherapy, wherein the IL-1β inhibitor is administered before immunotherapy.
(FR) La présente invention concerne l'utilisation d'un inhibiteur d'IL-1β pour la prévention et/ou le traitement de la neurotoxicité et/ou du syndrome de libération de cytokines chez un sujet suivant une immunothérapie, l'inhibiteur d'IL-1β étant administré avant l'immunothérapie.
Related patent documents
WO/2020/157498
US20220089724
# -